In summary, our analysis demonstrates that an unselected BRCA1/BRCA2/PALB2 multigene testing strategy is highly cost-effective in China, can prevent thousands of BC/OC cases/deaths, and provides a basis for policy change to implement this. This evidence concerns the gene PALB2 and breast cancer.